Biotechnology · Waltham, Massachusetts, United States
$9.21
-0.32% (-$0.03)2026-07-09
Smart-Money SignalNeutral · 51/100— Insider open-market flow is flat over 90 days
Revenue$12.6M
Net Income-$9.5M
EPS$-0.58
Market Cap$53.3M
Price Performance
Historical data including institutional events
Company Profile
R
Rene Russo
CEO & Executive Director
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.
The companyâs checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.
It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies.
The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
